A randomized trial was effected to evaluate the therapeutical efficacy of three different IFN types (r-Alfa 2b IFN, Alfa-N1-IFN e Beta-IFN) in long-term therapy (12 months) in 65 pts. (39 males and 26 females; mean age ± SD = 51.9 ± 12.7) afflicted with chronic C hepatitis. Patients (mean Scheuer score: 51.9 ± 12.7) are divided into three groups. In first group (22 pts. = 33.84%) r-Alfa 2b IFN (3 M.U. TIW) was used; second group (23 pts. = 35.38%) was treated with Alfa-N1-IFN (3 M.U. TIW), while Beta-IFN (3 M.U. TIW) was used in third group (20 pts. = 30.38%). Patients which showed normalization in ALT level during or at the end of treatment, were defined 'responders' and if this normalization persisted during follow-up interval of 12 months after the end of therapy, they were defined 'sustained responders'. In the first group 16 'responders' (72.73%) and 13 'sustained responders' (59.09%) were achieved, 11 'responders' (42.82%) and 7 'sustained responders' (30.43%) in the second group and 4 'responders' (20%) and 3 'sustained responders' (15%) in the third group. Both Alfa IFN achieved a significantly higher rate of 'responders' than Beta IFN. Regarding 'sustained responders', rAlfa IFN achieved a significantly higher efficacy than Alfa N1-IFN (p=0.05) and Beta-IFN (p=0.003). After correction for the significative pretreatment variables, multivariate analysis also confirmed these results (logistic analysis), while no pretreatment variables (such as age, Scheuer score, pattern RIBA, Gamma GT value) showed significant effects on the response rate.
|Translated title of the contribution||r Alfa-2b IFN vs. Alfa-N1 IFN and H-Beta IFN in chronic hepatitis C therapy|
|Number of pages||6|
|Journal||Giornale di Malattie Infettive e Parassitarie|
|Publication status||Published - 1994|
ASJC Scopus subject areas